Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Aminocaproic acid
Drug ID BADD_D00106
Description An antifibrinolytic agent that acts by inhibiting plasminogen activators which have fibrinolytic properties.
Indications and Usage For use in the treatment of excessive postoperative bleeding.
Marketing Status approved; investigational
ATC Code B02AA01
DrugBank ID DB00513
KEGG ID D00160
MeSH ID D015119
PubChem ID 564
TTD Drug ID D0FD0H
NDC Product Code 59285-019; 69766-054; 0517-9120; 0517-9191; 72205-049; 47621-310; 60687-529; 69238-1637; 69539-161; 69680-116; 80005-128; 46438-0641; 54288-151; 60687-739; 0404-9812; 69680-115; 70377-104; 76055-0030; 17478-447; 49411-050; 80005-129; 65571-0025; 70966-0010; 31722-035; 42799-054; 49411-052; 0409-4346; 62559-225; 69238-1596; 73216-110; 71052-265; 17478-768; 59651-573; 60687-724; 66689-330; 70377-102; 70377-103; 80005-130; 17478-769; 73216-111; 0904-7165; 72572-015; 49411-051; 51672-4226; 52817-815
UNII U6F3787206
Synonyms Aminocaproic Acid | 6-Aminohexanoic Acid | 6 Aminohexanoic Acid | epsilon-Aminocaproic Acid | epsilon Aminocaproic Acid | 6-Aminocaproic Acid | 6 Aminocaproic Acid | Capralense | Capramol | Caproamin | Caprocid | Hexalense | CY-116 | CY 116 | CY116 | Epsamon | Epsikapron | Hemocaprol | Amicar | Caprolest
Chemical Information
Molecular Formula C6H13NO2
CAS Registry Number 60-32-2
SMILES C(CCC(=O)O)CCN
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hepatotoxicity09.01.07.009; 12.03.01.008---
Hypersensitivity10.01.03.003--
Hypotension24.06.03.0020.000732%
Hypoxia22.02.02.0030.000229%
Injection site reaction08.02.03.014; 12.07.03.015--
Intracranial pressure increased17.07.02.002---
Lacrimation increased06.08.02.004--
Leukopenia01.02.02.001---
Liver function test abnormal13.03.04.030---
Local reaction08.01.03.012---
Loss of consciousness17.02.04.0040.000229%-
Malaise08.01.01.003--
Mouth haemorrhage07.05.02.001; 24.07.02.0140.000686%
Muscular weakness15.05.06.001; 17.05.03.005--
Myalgia15.05.02.001--
Myopathy15.05.05.001---
Myositis15.05.01.001--
Nasal congestion22.04.04.001--
Nausea07.01.07.0010.000617%
Necrosis08.03.03.001; 24.04.02.006---
Nervousness19.06.02.0030.000229%-
Oedema08.01.07.006; 14.05.06.010---
Pain08.01.08.004--
Pain in extremity15.03.04.0100.000229%
Peripheral ischaemia24.04.03.002--
Pruritus23.03.12.001--
Pulmonary embolism22.06.02.001; 24.01.06.0010.000229%-
Pyrexia08.05.02.0030.000503%
Rash23.03.13.001---
Renal failure20.01.03.005---
The 2th Page    First    Pre   2 3    Next   Last    Total 3 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene